Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

Zantac was originated by GSK and launched by ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns ...

The new 102-page opinion contradicts a December 2022 federal court ruling which dismissed all cases alleging five cancer types. The complaints revolve around allegations that Zantac and other ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK’s American depositary receipts rose as much as 9.9% in New York after the agreement was announced. GSK is among a number of companies that made and sold versions of Zantac, and investor ...

(WJET/WFXP) — UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now ...

Additionally, GSK has reached an agreement in principle to pay a total of $70 million to settle a Zantac qui tam complaint ... 1990s by Andrew Mariathasan in New York, with the goal of covering ...

Some top local politicians cut the ribbon Monday for a New Haven lab that works to test everyday products to make sure they ...